Get the Stockscreener App
29.64
2.98%
-0.91
Newamsterdam Pharma Company Nv stock is traded at $29.64, with a volume of 1.09M.
It is down -2.98% in the last 24 hours and down -9.16% over the past month.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
See More
Previous Close:
$30.55
Open:
$30.87
24h Volume:
1.09M
Relative Volume:
0.85
Market Cap:
$3.47B
Revenue:
$22.57M
Net Income/Loss:
$-212.73M
P/E Ratio:
-16.43
EPS:
-1.8045
Net Cash Flow:
$-142.19M
1W Performance:
-6.44%
1M Performance:
-9.16%
6M Performance:
-11.04%
1Y Performance:
+26.72%
1-Day Range:
$29.61
$31.17
1-Week Range:
$29.55
$32.62
52-Week Range:
$21.14
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Name
Newamsterdam Pharma Company Nv
Sector
Industry
Phone
35 206 2971
Address
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
29.64 | 3.47B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | Truist | Buy |
| Oct-20-25 | Resumed | H.C. Wainwright | Buy |
| Aug-25-25 | Initiated | Wells Fargo | Overweight |
| Jul-17-25 | Initiated | Goldman | Neutral |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Jun-10-25 | Initiated | Stifel | Buy |
| Jun-04-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| May-15-24 | Initiated | TD Cowen | Buy |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Jan-18-24 | Initiated | Guggenheim | Buy |
| Jan-16-24 | Initiated | Piper Sandler | Overweight |
| Oct-30-23 | Initiated | RBC Capital Mkts | Outperform |
View All
Newamsterdam Pharma Company Nv Stock (NAMS) Latest News
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26 - TradingView
Europe's drug committee recommends two NewAmsterdam cholesterol treatments - Stock Titan
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
NewAmsterdam Pharma Company (NAMS) Q1 2026 earnings summary - Quartr
NewAmsterdam Pharma Announces COO Transition and Advisory Role - TipRanks
NewAmsterdam Pharma's COO Douglas Kling to Leave for CEO Role at Another Clinical-Stage Biotech Company - Kalkine Media
Form 4 NewAmsterdam Pharma Co N.V. For: 22 July By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma (NAMS) COO Douglas Kling to step down Aug 14 - Stock Titan
NewAmsterdam Pharma (NAMS) CAO trades 105000 shares under 10b5-1 plan - Stock Titan
NewAmsterdam Pharma Company N.V. Announces Resignation of Douglas Kling from Chief Operating Officer, Effective August 14, 2026 - marketscreener.com
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView
NewAmsterdam Pharma Company (NAMS) Citi Annual Global Healthcare Conference 2025 summary - Quartr
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data By Investing.com - Investing.com Nigeria
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data - Investing.com
Responsive Playbooks and the NAMS Inflection - Stock Traders Daily
NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation - Bitget
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Drops 5.6% as Selling Pressure IntensifiesLarge Cap Trends - dars.gov.et
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Dips Amidst Sector Rotation; Key Support in FocusFundamental Weighted - dars.gov.et
NewAmsterdam Pharma Company (NAMS) Jefferies Global Healthcare Conference 2025 summary - Quartr
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data - t.co
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NewAmsterdam Pharma awards stock incentives to four new hires - Stock Titan
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. - TradingView
NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026 - Stock Titan
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView
NAMS Forecast — Price Target — Prediction for 2027 - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView
Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
Newamsterdam Pharma Company Nv Stock (NAMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):